CELLMID

ASX ANNOUNCEMENT

INDEPENDENT TEST RESULTS FOR THE WONDFO SARS-CoV-2 TEST

- **Wondfo's SARS-VoC-2 diagnostic was tested by The National Institute of Virology of the Indian Council of Medical Research**
- **Wondfo's test detected antibodies as early as day 3 from COVID-19 symptoms**
- **100% of samples (14) from day 6 of disease onset tested positive for antibodies**
- **There was no cross reactivity (false positives) detected**
- **Results are consistent with Wondfo's study of 596 COVID-19 patient samples**

SYDNEY, Wednesday, 22 April 2020: Cellmid Limited (ASX: CDY) has previously signed an agreement with Australia Applications, Wondfo's Australian agent, for the supply of the Wondfo SARS-CoV-2A point of care tests (POCT) in Australia (ASX Announcement, 27 March 2020. The Company here reports on the results of the independent testing of the POCT's by the National Institute of Virology of the Indian Council of Medical Research. The Institute is also a Collaborating Centre for Emerging Viral Infections by the World Health Organization.

The validation study was conducted on 24 individual samples of COVID-19 patients from day 2 to day 13 from the onset of symptoms, following confirmation of viral load using nucleotide testing. Another 12 samples positive for other related and non-related viruses were used as controls for cross reactivity.

The POCT has detected SARS-CoV-2 antibodies as early as day 3 from the onset of symptoms and accuracy improved with disease progression. The POCT has detected antibodies in all but one sample from day 4 following the onset of symptoms (6% false negatives). SARS-CoV-2 antibodies have been detected by the POCT in 100% of the samples from day 6 following the onset of symptoms, or approximately day 12 from exposure.

The control samples positive for other related and non-related viruses, but not for SARS-CoV-2, showed no cross reactivity. This means they were no false positives in the study. The study has been completed independently from Wondfo on samples and protocol selected by the National Institute of Virology in India. The high level of consistency observed in this study is especially relevant because of its smaller size.

The results of the study are consistent with Wondfo's 596 patient study earlier this year (ASX announcement, 27 March 2020) and underline the utility of the test in the management of the COVID-19 pandemic. These results only relate to the SARS-CoV-2 antibody tests manufactured by Wondfo Biotech and do not reflect performance of any other serological point of care tests on the market.

CELLMID LIMITED ACN 111 304 119 ASX I CDY
Suite 204, 55 Clarence Street, Sydney NSW 2000 AUSTRALIA
TELEPHONE +61 2 9221 6830 FACSIMILE +61 2 9221 8535
WEB www.cellmid.com.au

Wondfo SARS-CoV-2 POCT utility

The Wondfo Biotech manufactured SARS-CoV-2 point of care test detects antibodies to SARS-CoV-2, the virus which causes the COVID-19 disease. In addition to China the test is currently used in several countries including Germany, Spain and India.

In Australia PCR (polymerase chain reaction) is used as the current gold standard method for the diagnosis of acute COVID-19. PCR based nucleotide detection is reliant on accuracy of sampling. If there is virus in the collected sample PCR is highly accurate, however the success of sampling depends on the person taking the sample, the patient's stage in the disease and their individual manifestation.

A recent study by Zhao et al, funded by the Bill and Melinda Gates Foundation and published in the journal Clinical Infectious Diseases, 2020, showed that RNA based sampling only detected the virus successfully 67% of the time in the first week after onset of symptoms, falling to 46% in week 2. The study showed that by combining antibody-based screening methods with PCR, detection rates of COVID-19 were improved ($p<0.001$), even in very early disease in days 0-7 ($p=0.007$).

The Cellmid sponsored Wondfo SARS-CoV-2 kit is manufactured to the highest standards in a facility certified by the Australian Therapeutic Goods Administration (TGA), the US Food and Drug Administration (FDA) and the Chinese National Medical Products Administration (NMPA) under the Medical Device Single Audit Program (MDSAP). Wondfo's facility is in China and has an export certificate issued by the Chinese government.

Approved for release by the Board of Directors.

Contact:
Maria Halasz, CEO
T +612 9221 6830
@mariahalasz

Cellmid Limited (ASX: CDY)
Cellmid is an Australian life sciences company with a consumer health business and biotech assets in development. Advangen is Cellmid's wholly owned subsidiary engaged in the development and sale of first in class, best in class, clinically validated anti-aging products for hair, skin and body. For further information, please see www.cellmid.com.au and www.evolisproducts.com.au. Cellmid's wholly owned subsidiary, Lyramid, develops innovative novel therapies and diagnostic tests for age related diseases including inflammatory and autoimmune conditions. Most recently the Company commenced sale of a point of care diagnostic tests for COVID-19.

Forward looking statements
This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as the availability of resources, regulatory environment, the results of marketing and sales activities and competition.